Research & Literature

An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document.

Campistol JM, Arias M, Ariceta G, et al.

Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia 2015; (35(5)):421-47.

Effect of ADAMTS13 activity turnaround time on plasma utilization for suspected thrombotic thrombocytopenic purpura.

Connell NT, Cheves T, Sweeney JD

Transfusion 2016; (56(2)):354-9 doi:10.1111/trf.13359.

ATYPICAL HEMOLYTIC UREMIC SYNDROME IN AN ADULT SUCCESSFULLY TREATED WITH ECULIZUMAB.

Chaudoir C, Ong MG, Gu X, et al.

The Journal of the Louisiana State Medical Society : official organ of the Louisiana State Medical Society 2016; (168(1)):12-5.

[Atypical hemolytic uremic syndrome (aHUS): new insights into pathogenesis leading to novel therapeutic approaches].

Kistler AD

Praxis 2016; (105(7)):389-96 doi:10.1024/1661-8157/a002308.

Pathogenic Variants in Complement Genes and Risk of Atypical Hemolytic Uremic Syndrome Relapse after Eculizumab Discontinuation.

Fakhouri F, Fila M, Provôt F, et al.

Clinical journal of the American Society of Nephrology : CJASN 2017; (12(1)):50-59 doi:10.2215/CJN.06440616.

Case report - atypical hemolytic uremic syndrome triggered by influenza B.

Kobbe R, Schild R, Christner M, et al.

BMC nephrology 2017; (18(1)):96 doi:10.1186/s12882-017-0512-y.

Unusual severe case of hemolytic uremic syndrome due to Shiga toxin 2d-producing E. coli O80:H2.

Wijnsma KL, Schijvens AM, Rossen JWA, et al.

Pediatric nephrology (Berlin, Germany) 2017; (32(7)):1263-1268 doi:10.1007/s00467-017-3642-3.

Atypical Hemolytic Uremic Syndrome: A Brief Review.

Zhang K, Lu Y, Harley KT, Tran MH

Hematology reports 2017; (9(2)):7053 doi:10.4081/hr.2017.7053.

A new therapeutic strategy for atypical HUS.

Moake JL

Blood 2017; (130(3)):243-244 doi:10.1182/blood-2017-06-783704.

Clinical characteristics and genetic backgrounds of Japanese patients with atypical hemolytic uremic syndrome.

Fujisawa M, Kato H, Yoshida Y, et al.

Clinical and experimental nephrology 2018; (22(5)):1088-1099 doi:10.1007/s10157-018-1549-3.

Adverse outcomes in obstetric-atypical haemolytic uraemic syndrome: a case series analysis.

Kozlovskaya NL, Korotchaeva YV, Bobrova LA

The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians 2019; (32(17)):2853-2859 doi:10.1080/14767058.2018.1450381.

Mutations in membrane cofactor protein (CD46) gene in Indian children with hemolytic uremic syndrome.

Khandelwal P, Birla S, Bhatia D, et al.

Clinical kidney journal 2018; (11(2)):198-203 doi:10.1093/ckj/sfx078.

Atypical Hemolytic Uremic Syndrome.

Dixon BP, Gruppo RA

Pediatric clinics of North America 2018; (65(3)):509-525 doi:10.1016/j.pcl.2018.02.003.

The Differential Diagnosis and Treatment of Thrombotic Microangiopathies.

Bommer M, Wölfle-Guter M, Bohl S, Kuchenbauer F

Deutsches Arzteblatt international 2018; (115(19)):327-334.

Combined study of ADAMTS13 and complement genes in the diagnosis of thrombotic microangiopathies using next-generation sequencing.

Fidalgo T, Martinho P, Pinto CS, et al.

Research and practice in thrombosis and haemostasis 2017; (1(1)):69-80 doi:10.1002/rth2.12016.

When to Stop Eculizumab in Complement-Mediated Thrombotic Microangiopathies.

Olson SR, Lu E, Sulpizio E, et al.

American journal of nephrology 2018; (48(2)):96-107 doi:10.1159/000492033.

Hypertensive Crisis and Refractory Hypertension Caused by Atypical Hemolytic Uremic Syndrome and Effect of Eculizumab.

Chen FY, Chen CH, Lin CC

Acta Cardiologica Sinica 2018; (34(5)):446-449 doi:10.6515/ACS.201809_34(5).20180326D.

Diagnostic Utility of Complement Serology for Atypical Hemolytic Uremic Syndrome.

Sridharan M, Go RS, Abraham RS, et al.

Mayo Clinic proceedings 2018; (93(10)):1351-1362 doi:10.1016/j.mayocp.2018.07.008.

Thrombotic microangiopathy following Bothrops jararaca snakebite: case report.

Bucaretchi F, Pimenta MMB, Borrasca-Fernandes CF, et al.

Clinical toxicology (Philadelphia, Pa.) 2019; (57(4)):294-299 doi:10.1080/15563650.2018.1514621.

Atypical hemolytic-uremic syndrome: recurrent phenotypic expression of a patient with MCP gene mutation combined with risk haplotypes.

Marini SC, Gomes M, Guilherme R, et al.

Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 2019; (30(2)):68-70 doi:10.1097/MBC.0000000000000793.

Membrane-filtration based plasma exchanges for atypical hemolytic uremic syndrome: Audit of efficacy and safety.

Khandelwal P, Thomas CC, Rathi BS, et al.

Journal of clinical apheresis 2019; (34(5)):555-562 doi:10.1002/jca.21711.

Outcomes of Kidney Transplant Patients with Atypical Hemolytic Uremic Syndrome Treated with Eculizumab: A Systematic Review and Meta-Analysis.

Gonzalez Suarez ML, Thongprayoon C, Mao MA, et al.

Journal of clinical medicine 2019; (8(7)) doi:10.3390/jcm8070919.

Atypical Hemolytic Uremic Syndrome: A Case Report.

Mohammed SK, Mubarik A, Nadeem B, et al.

Cureus 2019; (11(5)):e4634 doi:10.7759/cureus.4634.

Burden of caregiving and its impact in the patients of acute lymphoblastic leukemia.

Kumari R, Kohli A, Malhotra P, et al.

Industrial psychiatry journal 2018; (27(2)):249-258 doi:10.4103/ipj.ipj_75_18.

Is eculizumab indicated in patients with atypical hemolytic uremic syndrome already on prolonged dialysis? A case report and review of the literature.

Haskin O, Falush Y, Davidovits M

Pediatric nephrology (Berlin, Germany) 2019; (34(12)):2601-2604 doi:10.1007/s00467-019-04341-4.

Rapid culture-based identification of Shiga toxin-producing Escherichia coli and Shigella spp./Enteroinvasive E. coli using the eazyplex® EHEC complete assay.

Penzel A, Schützler K, Dröge J, et al.

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 2020; (39(1)):151-158 doi:10.1007/s10096-019-03704-x.

[Diagnostic and Therapeutic Challenges in Atypical Hemolytic Uremic Syndrome: A Case Report].

Reis S, Ramos D, Cordinhã C, Gomes C

Acta medica portuguesa 2019; (32(10)):673-675 doi:10.20344/amp.10021.

Complement Activation and Thrombotic Microangiopathies.

Palomo M, Blasco M, Molina P, et al.

Clinical journal of the American Society of Nephrology : CJASN 2019; (14(12)):1719-1732 doi:10.2215/CJN.05830519.

Genetics and outcome of atypical hemolytic-uremic syndrome in Turkish children: a retrospective study between 2010 and 2017, a single-center experience.

Conkar S, Mir S, Berdeli A

Iranian journal of kidney diseases 2019; (13(5)):316-321.

Prognostic utility of ADAMTS13 activity for the atypical hemolytic uremic syndrome (aHUS) and comparison of complement serology between aHUS and thrombotic thrombocytopenic purpura.

Oh J, Oh D, Lee SJ, et al.

Blood research 2019; (54(3)):218-228 doi:10.5045/br.2019.54.3.218.

The role of anti-complement factor H antibodies in the development of atypical haemolytic uremic syndrome: a possible contribution to abnormality of platelet function.

Fujisawa M, Yasumoto A, Kato H, et al.

British journal of haematology 2020; (189(1)):182-186 doi:10.1111/bjh.16297.

Atypical Hemolytic Uremic Syndrome following Acute Type A Aortic Dissection.

Ikushima E, Hisahara M, Nishijima T, et al.

Case reports in hematology 2020; (2020()):2467953 doi:10.1155/2020/2467953.

Epidemiology of Atypical Hemolytic Uremic Syndrome: A Systematic Literature Review.

Yan K, Desai K, Gullapalli L, et al.

Clinical epidemiology 2020; (12()):295-305 doi:10.2147/CLEP.S245642.

Molecular basis and outcomes of atypical haemolytic uraemic syndrome in Czech children.

Štolbová Š, Bezdíčka M, Seeman T, et al.

European journal of pediatrics 2020; (179(11)):1739-1750 doi:10.1007/s00431-020-03666-9.

A case report of recurrent acute pancreatitis associated with life threatening atypical hemolytic uremic syndrome.

Jean-Marie EM, Cho JJ, Trevino JG

Medicine 2020; (99(22)):e19731 doi:10.1097/MD.0000000000019731.

Eculizumab and aHUS: Spotlight on Patient-Centered Care.

Rafat C, Luque Y

Kidney international reports 2020; (5(8)):1123-1125 doi:10.1016/j.ekir.2020.06.007.

Distinct genetic profile with recurrent population-specific missense variants in Korean adult atypical hemolytic uremic syndrome.

Yun JW, Oh J, Lee KO, et al.

Thrombosis research 2020; (194()):45-53 doi:10.1016/j.thromres.2020.06.016.

Eculizumab discontinuation in children and adults with atypical hemolytic-uremic syndrome: a prospective multicenter study.

Fakhouri F, Fila M, Hummel A, et al.

Blood 2021; (137(18)):2438-2449 doi:10.1182/blood.2020009280.

Haemoglobinuria for the early identification of aHUS relapse: data from the ItalKId-HUS Network.

Brambilla M, Ardissino G, Paglialonga F, et al.

Journal of nephrology 2022; (35(1)):279-284 doi:10.1007/s40620-021-00965-8.

Diagnosis and follow-up of thrombotic thrombocytopenic purpura with an automated chemiluminescent ADAMTS13 activity immunoassay.

Beranger N, Benghezal S, Joly BS, et al.

Research and practice in thrombosis and haemostasis 2021; (5(1)):81-93 doi:10.1002/rth2.12461.

Clinical and Genetic Characteristics of Atypical Hemolytic Uremic Syndrome in Children: A Chinese Cohort Study.

Wu D, Chen J, Ling C, et al.

Nephron 2021; (145(4)):415-427 doi:10.1159/000513009.

Altered Theory of Mind in Parkinson's Disease and Impact on Caregivers: A Pilot Study.

Giguère-Rancourt A, Plourde M, Racine E, et al.

The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques 2022; (49(3)):437-440 doi:10.1017/cjn.2021.110.

Functional characterization of 105 factor H variants associated with aHUS: lessons for variant classification.

Martín Merinero H, Zhang Y, Arjona E, et al.

Blood 2021; (138(22)):2185-2201 doi:10.1182/blood.2021012037.

Discontinuation of Eculizumab treatment after hematological remission in patients with atypical and drug-induced hemolytic uremic syndrome.

Yeter HH, Derici U, Arinsoy T, et al.

Romanian journal of internal medicine = Revue roumaine de medecine interne 2022; (60(1)):56-65 doi:10.2478/rjim-2021-0034.

Case series: coronavirus disease 2019 infection as a precipitant of atypical hemolytic uremic syndrome: two case reports.

Kurian CJ, French Z, Kukulich P, et al.

Journal of medical case reports 2021; (15(1)):587 doi:10.1186/s13256-021-03144-2.

POSTPARTUM RENAL THROMBOTIC MICROANGIOPATHY: A TURN-BASED DIFFERENTIAL DIAGNOSIS.

Markin L, Shatylovych K

Wiadomosci lekarskie (Warsaw, Poland : 1960) 2022; (75(1)):128-131.

A novel missense mutation in complement factor I predisposes patients to atypical hemolytic uremic syndrome: a case report.

Wei X, Li J, Zhan X, et al.

Journal of medical case reports 2022; (16(1)):101 doi:10.1186/s13256-022-03312-y.

Ravulizumab 100 mg/mL formulation reduces infusion time and frequency, improving the patient and caregiver experience in the treatment of atypical haemolytic uraemic syndrome.

Dixon BP, Sabus A

Journal of clinical pharmacy and therapeutics 2022; (47(7)):1081-1087 doi:10.1111/jcpt.13642.

Clinical features of children with anti-CFH autoantibody-associated hemolytic uremic syndrome: a report of 8 cases.

Li Q, Kong X, Tian M, et al.

Renal failure 2022; (44(1)):1061-1069 doi:10.1080/0886022X.2022.2089167.

The Importance of Eculizumab in the Treatment of Atypical Hemolytic Uremic Syndrome.

Santos MS, Ventura S, Alves A, et al.

Cureus 2022; (14(6)):e25743 doi:10.7759/cureus.25743.

Novel Complement Factor B Gene Mutation Identified in a Kidney Transplant Recipient with a Shiga Toxin-Triggered Episode of Thrombotic Microangiopathy.

Korzycka J, Pawłowicz-Szlarska E, Masajtis-Zagajewska A, Nowicki M

The American journal of case reports 2022; (23()):e936565 doi:10.12659/AJCR.936565.

Three shades of black - secondary thrombotic microangiopathy.

Das R, Dasgupta S, Sengupta M, Basu K

Indian journal of pathology & microbiology 2022; (65(4)):898-901 doi:10.4103/ijpm.ijpm_1237_21.

Exploratory Prognostic Biomarkers of Complement-Mediated Thrombotic Microangiopathy (CM-TMA) in Adults with Atypical Hemolytic Uremic Syndrome (aHUS): Analysis of a Phase III Study of Ravulizumab.

Cammett TJ, Garlo K, Millman EE, et al.

Molecular diagnosis & therapy 2023; (27(1)):61-74 doi:10.1007/s40291-022-00620-3.

The Factor H protein family: The switchers of the complement alternative pathway.

Lucientes-Continente L, Márquez-Tirado B, Goicoechea de Jorge E

Immunological reviews 2023; (313(1)):25-45 doi:10.1111/imr.13166.

Comparison of clinical characteristics of first-episode thrombotic thrombocytopenic purpura and TTP-like syndrome: a retrospective cohort study in a level I hematology center in China.

Dong G, Shi FE, Yu J, Zhu J

Annals of hematology 2023; (102(1)):55-62 doi:10.1007/s00277-022-05030-3.

COVID-19 vaccination and Atypical hemolytic uremic syndrome.

Bouwmeester RN, Bormans EMG, Duineveld C, et al.

Frontiers in immunology 2022; (13()):1056153 doi:10.3389/fimmu.2022.1056153.

Pharmacological Management of Atypical Hemolytic Uremic Syndrome in Pediatric Patients: Current and Future.

Gurevich E, Landau D

Paediatric drugs 2023; (25(2)):193-202 doi:10.1007/s40272-022-00555-6.

Early Eculizumab Withdrawal in Patients With Atypical Hemolytic Uremic Syndrome in Native Kidneys Is Safe and Cost-Effective: Results of the CUREiHUS Study.

Bouwmeester RN, Duineveld C, Wijnsma KL, et al.

Kidney international reports 2023; (8(1)):91-102 doi:10.1016/j.ekir.2022.10.013.

Efficacy of cascade plasmapheresis in comparison with conventional therapeutic plasma exchange for relapsed atypical hemolytic uremic syndrome: A case report.

Vaidya A, Polavarapu I, Prabhu RA, et al.

Asian journal of transfusion science 2022; (16(2)):283-286 doi:10.4103/ajts.ajts_121_21.

Ravulizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder.

Pittock SJ, Barnett M, Bennett JL, et al.

Annals of neurology 2023; (93(6)):1053-1068 doi:10.1002/ana.26626.

Severe hypertension and (renal) thrombotic microangiopathy: solving the puzzle.

Wehrmann F, von Bergwelt-Baildon A, Schönermarck U

Journal of nephrology 2023; (36(8)):2175-2177 doi:10.1007/s40620-023-01659-z.

Constipation and hemolytic uremic syndrome.

Crawford B, Strebeck P, Saccente S

Pediatric nephrology (Berlin, Germany) 2024; (39(2)):603-607 doi:10.1007/s00467-023-06093-8.

Treatment preference and quality of life impact: ravulizumab vs eculizumab for atypical hemolytic uremic syndrome.

Mauch TJ, Chladek MR, Cataland S, et al.

Journal of comparative effectiveness research 2023; (12(9)):e230036 doi:10.57264/cer-2023-0036.

Diagnosis of Bone Marrow Necrosis following Severe Vaso-Occlusive Crisis in Patient with Compound Heterozygous Sickle Cell Disease.

Marco DN, Cid J, Garrote M, et al.

Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie 2023; (50(4)):360-364 doi:10.1159/000529500.

Coronavirus disease 2019-associated thrombotic microangiopathy treated with plasma exchange and antihypertensive therapy in a patient with HIV: A case report with literature review.

Masuda E, Fukushima K, Hebisawa Y, et al.

Medicine 2023; (102(41)):e35469 doi:10.1097/MD.0000000000035469.

Complement-Mediated Thrombotic Microangiopathy in Pregnancy: An Educational Case Report.

Bruno V, Barth D, Jauhal A

Canadian journal of kidney health and disease 2023; (10()):20543581231209009 doi:10.1177/20543581231209009.

Management of pediatric hemolytic uremic syndrome.

Gülhan B, Özaltın F, Fidan K, et al.

The Turkish journal of pediatrics 2024; (66(1)):1-16.

Bilateral Retinal Venous Occlusion in Atypical Hemolytic-Uremic Syndrome Due to Complement Factor H Mutation.

Gonul S, Eker S

Ocular immunology and inflammation 2024; (32(9)):2285-2289 doi:10.1080/09273948.2024.2333401.

Safety Profile of Monoclonal Antibodies and Subsequent Drug Developments in the Treatment of Paroxysmal Nocturnal Hemoglobinuria.

Mallenahalli Neeekantappa V, Kamath A, Bharathi Rajaduraivelpandian P

Medicina (Kaunas, Lithuania) 2024; (60(3)) doi:10.3390/medicina60030379.

Ravulizumab facilitates reduced burden of vascular access, a major benefit in paediatric atypical haemolytic uraemic syndrome.

Bleathman F, Kausman JY, Hosking LM, Forbes TA

Journal of paediatrics and child health 2024; (60(6)):183-187 doi:10.1111/jpc.16552.

Ravulizumab in Atypical Hemolytic Uremic Syndrome: An Analysis of 2-Year Efficacy and Safety Outcomes in 2 Phase 3 Trials.

Dixon BP, Kavanagh D, Aris ADM, et al.

Kidney medicine 2024; (6(8)):100855 doi:10.1016/j.xkme.2024.100855.

An expert discussion on the atypical hemolytic uremic syndrome nomenclature-identifying a road map to precision: a report of a National Kidney Foundation Working Group.

Nester CM, Feldman DL, Burwick R, et al.

Kidney international 2024; (106(3)):326-336 doi:10.1016/j.kint.2024.05.021.

The Phenomenon of Thrombotic Microangiopathy in Cancer Patients.

Vorobev A, Bitsadze V, Yagubova F, et al.

International journal of molecular sciences 2024; (25(16)) doi:10.3390/ijms25169055.

An evaluation of ravulizumab for the treatment of neuromyelitis optica spectrum disorder.

Balaban DT, Levy M, Borrow R, Anderson MR

Expert opinion on biological therapy 2024; (24(11)):1193-1198 doi:10.1080/14712598.2024.2423002.

Extrarenal manifestations of atypical hemolytic uremic syndrome: a systematic review and meta-analysis.

Doshi K, Yusuf A, Licht C, et al.

Pediatric research 2025; (98(2)):491-497 doi:10.1038/s41390-024-03771-7.

A Unique Presentation of Atypical Hemolytic Uremic Syndrome With Unilateral Blindness and Ischemic Stroke: A Case Report.

Girdhar K, Bansal DP, Rijhwani P, et al.

Cureus 2024; (16(11)):e73632 doi:10.7759/cureus.73632.

The role of the complement system in Shiga toxin-associated hemolytic uremic syndrome.

Bocanegra V, Luna M, Costantino VV, et al.

Pediatric nephrology (Berlin, Germany) 2025; (40(5)):1711-1722 doi:10.1007/s00467-024-06629-6.

Anxiety mediates the relationship between caregiver burden and preparedness in individuals with acquired brain injury: meta-analytic structural equation modeling.

Kuai S, Fan Y, Zhao Y, et al.

Brain injury 2025; (39(7)):539-550 doi:10.1080/02699052.2025.2456964.

[Atypical hemolytic uremic syndrome: differential diagnosis and therapy - A clinical practice guideline for diagnosis and therapy].

Gäckler A, Brinkkötter PT

Deutsche medizinische Wochenschrift (1946) 2025; (150(4)):167-172 doi:10.1055/a-2382-6433.

Atypical hemolytic uremic syndrome triggered by acute pancreatitis.

Yang Q, Geng Q, Chen S, et al.

Revista espanola de enfermedades digestivas 2025; doi:10.17235/reed.2025.11114/2025.

Multidisciplinary consensus on the diagnosis and management of patients with atypical Hemolytic Uremic Syndrome (complement-mediated TMA): Recommendations from Italian scientific societies, patient associations and regulators.

Stea ED, Pugliano M, Gualtierotti R, et al.

Pharmacological research 2025; (216()):107714 doi:10.1016/j.phrs.2025.107714.

The impact of caregiver burden on sense of coherence in Chinese family caregivers of people with dementia: the mediating effect of family resilience.

Jia H, Zhang J, Su W, et al.

BMC psychology 2025; (13(1)):369 doi:10.1186/s40359-025-02678-0.

Real-world use of complement inhibitors for haemolytic uraemic syndrome: an analysis of the European Rare Kidney Disease Registry cohort.

Vujović A, Sellier-Leclerc AL, Mancuso MC, et al.

EClinicalMedicine 2025; (82()):103159 doi:10.1016/j.eclinm.2025.103159.

Long-Term Outcomes of Anticomplement Factor H Antibody Positive Versus Negative Atypical Hemolytic Uremic Syndrome.

Veeranki V, Meyyappan J, Srivastava A, et al.

Indian journal of nephrology 2025; (35(3)):402-409 doi:10.25259/IJN_106_2024.

Atypical hemolytic uremic syndrome: a rare complication of postendoscopic retrograde cholangiopancreatography pancreatitis.

Nanagiri A, Pravder S, Solomon S, et al.

JPGN reports 2025; (6(2)):193-195 doi:10.1002/jpr3.70014.

Immune Thrombotic Thrombocytopenic Purpura: A Review.

Pishko AM, Li A, Cuker A

JAMA 2025; (334(6)):517-529 doi:10.1001/jama.2025.3807.

Hypertensive Emergency and Atypical Hemolytic Uremic Syndrome Associated with Cocaine Use: A Diagnostic and Therapeutic Challenge.

Jiménez Mayor E, De La Flor JC, Rocha Rodrigues A, et al.

Diseases (Basel, Switzerland) 2025; (13(5)) doi:10.3390/diseases13050153.

Impact of burnout and spiritual well-being on caregiver burden in parents of children with cancer.

Akbulut Uğur Aİ, Kızılırmak Tatu M

Journal of pediatric nursing 2025; (84()):208-216 doi:10.1016/j.pedn.2025.06.016.

A Case Report of Atypical Hemolytic Uremic Syndrome Presenting With Disseminated Intravascular Coagulation.

Brink HM, Wallworth TM, Penney SW, et al.

Cureus 2025; (17(7)):e87437 doi:10.7759/cureus.87437.

Microangiopathic Anemia.

Bommer M, Bloehdorn J

Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie 2025; (52(4)):259-270 doi:10.1159/000544724.

High prevalence of the hotspot complement factor I p.Ile357Met pathogenic variant in Tunisian atypical hemolytic uremic syndrome patients: report of three new cases and review of the literature.

Tajouri A, Ayadi I, BenBrahim R, et al.

Frontiers in immunology 2025; (16()):1623432 doi:10.3389/fimmu.2025.1623432.

C3 p.Asp1115Asn Variant-associated Atypical Hemolytic Uremic Syndrome with Spontaneous Remission Triggered by Influenza and COVID-19.

Fujino Y, Hanada H, Takata T, et al.

Internal medicine (Tokyo, Japan) 2026; (65(8)):1152-1157 doi:10.2169/internalmedicine.6036-25.

[Ultra-early administration of eculizumab in a child with atypical hemolytic uremic syndrome: a case report].

Guo DD, Xiao YX, Wang WR, et al.

Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics 2025; (27(11)):1408-1413 doi:10.7499/j.issn.1008-8830.2503084.

Serology as an early diagnostic tool in pediatric patients with Shiga toxin-producing Escherichia coli-associated hemolytic uremic syndrome: a post hoc analysis of a phase 2 clinical trial.

Landivar SM, Melli LJ, Pichel M, et al.

Journal of clinical microbiology 2026; (64(4)):e0141525 doi:10.1128/jcm.01415-25.